Logo

American Heart Association

  2
  0


Final ID: MDP1435

Targeting Tyrosine Kinase Inhibitor-Associated Cardiotoxicity with NPA7: A Novel Dual Activating Peptide

Abstract Body (Do not enter title and authors here): Background: Tyrosine kinase inhibitors (TKIs), such as sunitinib, are highly effective in treating cancers. However, they have severe cardiovascular (CV) side effects that include cardiotoxicity via cardiomyocyte injury and death resulting in myocardial dysfunction. There are no FDA-approved drugs to prevent or treat cardiotoxicity, which have been linked mechanistically to mitochondrial dysfunction and oxidative stress, highlighting the need for new therapeutics. Two recognized CV protective pathways are the particulate guanylyl cyclase A receptor (GC-A)/cGMP and the Mas receptor (MasR)/cAMP pathways. We recently engineered NPA7 a novel peptide that activates both pathways.
Aim: Here we investigated NPA7’s ability to protect against sunitinib-induced cardiotoxicity in human cardiomyocytes (HCMs) and defined its role on mitochondrial function.
Methods: HCMs were treated with DMSO or sunitinib (10 µM) together with PBS or NPA7 (10 µM). Intracellular reactive oxygen species (ROS) was assessed by DHE staining. CCK8 assay was performed to measure cell viability. TOM20 staining were performed by immunofluorescence and the mitochondrial length was analyzed. The protein levels of mitochondrial dynamics markers (fission: MFF, Fis1; fusion: OPA1 and MFN1) proteins were measured by western blot. Cell surface area was assessed by phalloidin staining with mRNA levels of hypertrophic gene markers (NPPA and MYH7) in HCMs using real-time PCR.

Results: Sunitinib increased DHE staining and intracellular ROS in HCMs, which was decreased with NPA7 treatment. NPA7 enhanced HCM cell viability in the presence of sunitinib. TOM20 staining showed a marked reduction in mitochondrial length in sunitinib group, compared to DMSO group, whereas NPA7 treatment rescued mitochondria length (DMSO= 6.15 ± 0.94 μm, Sunitinib= 2.42 ± 0.63 μm, NPA7= 5.4 ± 1.19 μm; P < 0.05). Moreover, NPA7 inhibited mitochondrial fission protein levels (MFF and Fis1) and increased mitochondrial fusion protein levels (OPA1, MFN1) in HCMs treated with sunitinib. Sunitinib treatment notably increased HCM cell surface area and hypertrophic gene markers (NPPA and MYH7), whereas NPA7 abolished these markers of hypertrophy.

Conclusions: We report, for the first time, that NPA7 protects against sunitinib induced oxidative stress, mitochondrial fragmentation, hypertrophy and cell death in HCMs. These data support a novel therapeutic approach against TKI-induced cardiotoxicity with NPA7 to which no therapies exist.
  • Ma, Xiaoyu  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Malsawmzuali, Jc  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Moroni, Dante  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Zheng, Ye  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Sangaralingham, Jeson  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Burnett, John  ( MAYO CLINIC FOUNDATION , Rochester , Minnesota , United States )
  • Author Disclosures:
    Xiaoyu Ma: DO NOT have relevant financial relationships | JC Malsawmzuali: DO NOT have relevant financial relationships | Dante Moroni: DO NOT have relevant financial relationships | Ye Zheng: DO have relevant financial relationships ; Employee:Mayo Clinic:Active (exists now) | Jeson Sangaralingham: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Royalties/Patent Beneficiary:E-Star Biotech:Active (exists now) ; Advisor:E-Star Biotech:Active (exists now) ; Royalties/Patent Beneficiary:AlloRock:Active (exists now) ; Advisor:AlloRock:Active (exists now) | John Burnett: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

GDMT and Beyond - Is It Protective in Cancer?

Monday, 11/18/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
Attenuating Post-stroke Ischemia Reperfusion Injury: Establishing the Efficacy of Disodium Malonate in a Clinically Relevant Sheep Model

Sorby-adams Annabel, Murphy Mike, Sharkey Jessica, Prag Hiran, Turner Renee, Skein Keziah, Guglietti Bianca, Pullan Caitlin, Williams Georgia, Krieg Thomas

Acetylation of Mitochondrial Cyclophilin D Increases vascular Oxidative Stress, Induces Glycolitic Switch, Promotes Endothelial Dysfunction and Hypertension

Dikalov Sergey, Sack Michael, Dikalova Anna, Fehrenbach Daniel, Mayorov Vladimir, Panov Alexander, Ao Mingfang, Lantier Louise, Amarnath Venkataraman, Lopez Marcos, Billings Frederic

You have to be authorized to contact abstract author. Please, Login
Not Available